Dianthus Therapeutics, Inc.
NASDAQ:DNTHBiotechnology
-$1.03 today
- Market cap
- $4.73B
- Beta
- 0.07
- P/E (TTM)
- -343.0
- EPS (TTM)
- -$0.24
Volume 0.84M
Average 0.82M
DNTH Stock-Based Compensation
Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.
Dianthus Therapeutics, Inc.NASDAQ: DNTH
Stock-Based Compensation · Q2 FY2026 · quarter ended Jun 2026
Stock-based compensation growth accelerates
Q2 FY2026 stock-based compensation of $11.9M rose 108.5% year over year, ahead of the +82.5% change in trailing-twelve-month stock-based compensation. Sequentially, it rose 12.2% from the prior quarter. Over 3 fiscal years it compounded at +146.7% a year.
Context
- Stock-based compensation amounted to 1119.5% of revenue in FY2025, up 912.7 pp from a year earlier.
- Stock-based compensation increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +108.5% holds above the trailing-twelve-month pace of +82.5%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Stock-Based Compensation history
USD · from the cash flow
- Latest · FY2025
- 22.79M USD
- Year-over-year change
- +76.8%
| Period | Period end | Stock-Based Compensation | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 22.79M | +76.8% |
| FY2024 | 2024-12-31 | 12.89M | +344.6% |
| FY2023 | 2023-12-31 | 2.9M | +91.0% |
| FY2022 | 2022-12-31 | 1.52M | — |
| FY2021 | 2021-12-31 | 0 | — |
Stock-Based Compensation vs competitors
How DNTH compares with its peers on the latest reported figures
- DNTH's LTM Jun 2026 stock-based compensation of $34.27M is the 5th largest of the 10 companies compared; the peer median is $23.96M.
- Its year-over-year change of +82.5% is the 2nd highest of 10, against a peer median of -7.4%.
- Stock-based compensation amounts to 1800.0% of revenue for DNTH, versus a peer median of 540.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $50.91M | -7.8% | +19.9% | 717.6% | |
| LTM Jun 2026 | $49.78M | +71.5% | +62.2% | — | |
| LTM Mar 2026 | $41.12M | +24.3% | +9.7% | 17.7% | |
ALMSAlumis Inc. Common Stock | LTM Jun 2026 | $36.4M | -7.4% | +94.0% | 492.0% |
| LTM Jun 2026 | $34.27M | +82.5% | +146.7% | 1800.0% | |
| LTM Mar 2026 | $23.96M | +203.5% | +10.1% | — | |
| LTM Mar 2026 | $10.44M | +36.3% | -2.0% | 587.9% | |
ARTVArtiva Biotherapeutics, Inc. | LTM Mar 2026 | $6.36M | -16.6% | +1.2% | — |
| LTM Mar 2026 | $3.99M | -24.8% | +61.9% | 7.4% | |
| FY2025 | $3.73M | -44.6% | +54.6% | 5821.9% | |
| Peer median (excluding DNTH) | $23.96M | -7.4% | +19.9% | 540.0% | |
Competitors are the stored peer set for DNTH. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (71.14M) | (28.48M) | (43.56M) | (84.97M) | (162.34M) |
| Depreciation & Amortization | 2.02M | 147K | 355K | 412K | 428K |
| Deferred Income Tax | 0 | 0 | (661K) | 0 | 0 |
| Stock-Based Compensation | 0 | 1.52M | 2.9M | 12.89M | 22.79M |
| Change in Working Capital | (1.53M) | (1.65M) | 4.86M | (351K) | 16.73M |
| Accounts Receivables | 0 | (4.16M) | 5.16M | 0 | 755K |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | (720K) | 2.28M | 661K | 8.19M | 11.28M |
| Other Working Capital | (806K) | 229K | (959K) | (8.54M) | 4.69M |
| Other Non-Cash Items | 11.11M | (606K) | (762K) | (6.17M) | (6.67M) |
| Operating Cash Flow | (59.53M) | (29.07M) | (36.86M) | (78.18M) | (129.06M) |
| Capital Expenditures | (1.26M) | (139K) | (110K) | (105K) | (213K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | (45.31M) | (61.68M) | (57.42M) | (413.71M) | (435.01M) |
| Sales of Investments | 90M | 2M | 77.79M | 127M | 312.39M |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | 43.43M | (59.82M) | 20.25M | (286.81M) | (122.83M) |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 89.6M | 0 | 72M | 269.2M | 280.13M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | (3.32M) | 61.57M | (13.58M) | 0 |
| Financing Cash Flow | 89.6M | 96.68M | 133.57M | 255.62M | 280.13M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 73.5M | 7.79M | 116.97M | (109.37M) | 28.23M |
| Free Cash Flow | (60.8M) | (29.21M) | (36.97M) | (78.29M) | (129.27M) |
Dianthus Therapeutics, Inc.
NASDAQ:DNTH
Intrinsic Alpha fair value
Locked
Current Price
$83.98
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.